Igor Tsaur
Research Subjects
Igor Tsaur has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Axel Haferkamp
Mainz, Germany
8 shared publicationsHendrik Borgmann
Mainz, Germany
8 shared publicationsGeorg Bartsch
A Department of Urology , University of Mainz , Mainz , Germany
7 shared publicationsDavid Schilling
Department of Urology and Pediatric Urology, Goethe-University, Frankfurt am Main, Germany
4 shared publicationsRoman A. Blaheta
Department of Urology, Goethe-University, Frankfurt am Main, Germany
4 shared publicationsEva Juengel
Department of Urology, Goethe-University, Frankfurt am Main, Germany
3 shared publications
Latest Publications
- Open Access
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4) , e484-e485
PD23-12 UTILIZATION OF FACEBOOK, TWITTER, YOUTUBE AND INSTAGRAM IN THE PROSTATE CANCER COMMUNITY
To measure the usage rate of social media (SoMe) resources in the prostate cancer community, we performed a comprehensive quantitative and qualitative assessment of SoMe activity on the topic of PCa on the four most frequented platforms.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4) , e484-e485
Open AccessPD23-12 UTILIZATION OF FACEBOOK, TWITTER, YOUTUBE AND INSTAGRAM IN THE PROSTATE CANCER COMMUNITY
To measure the usage rate of social media (SoMe) resources in the prostate cancer community, we performed a comprehensive quantitative and qualitative assessment of SoMe activity on the topic of PCa on the four most frequented platforms.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4) , e659-e660
PD34-10 ATTRACTIVENESS AND ACCESSIBILITY OF FOCAL THERAPY FOR PROSTATE CANCER: RESULTS OF AN INTERNATIONAL WEB-BASED SURVEY
Focal therapy (FT) of localized prostate cancer (PCa) yields promising medium-term oncological and functional outcomes. FT role in multi-focal disease and in low-risk cancer suitable for active surveillance (AS), its recurrence rates and lack of long-term data remain open issues. Guidelines limit its use to clinical trials and FT is available only in a few academic centres. The urologists′ opinion over FT has never been investigated. We assessed the current opinion and accessibility of FT in the European urological community.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4) , e659-e660
PD34-10 ATTRACTIVENESS AND ACCESSIBILITY OF FOCAL THERAPY FOR PROSTATE CANCER: RESULTS OF AN INTERNATIONAL WEB-BASED SURVEY
Focal therapy (FT) of localized prostate cancer (PCa) yields promising medium-term oncological and functional outcomes. FT role in multi-focal disease and in low-risk cancer suitable for active surveillance (AS), its recurrence rates and lack of long-term data remain open issues. Guidelines limit its use to clinical trials and FT is available only in a few academic centres. The urologists′ opinion over FT has never been investigated. We assessed the current opinion and accessibility of FT in the European urological community.
- 11 April 2017
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 51 (4) , 342-344
Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain
(2017). Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain. Scandinavian Journal of Urology: Vol. 51, No. 4, pp. 342-344.
- 11 April 2017
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 51 (4) , 342-344
Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain
(2017). Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain. Scandinavian Journal of Urology: Vol. 51, No. 4, pp. 342-344.
- 1 February 2016
- Published by Elsevier in Life Sciences
- Vol. 147, 137-142
Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro
- 1 February 2016
- Published by Elsevier in Life Sciences
- Vol. 147, 137-142
Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro
- Open Access
- 10 November 2015
- Published by Springer Nature in Patient Safety in Surgery
- Vol. 9 (1) , 37
Utilization of surgical safety checklists by urological surgeons in Germany: a nationwide prospective survey
We aimed to investigate the contemporary usage rate and habits of the WHO Surgical Safety Checklist (SSC) in German urological departments. We designed a 26-item questionnaire that was sent to all urological departments in Germany. The primary aim of this study was to evaluate the usage rate of the SSC. Secondary aims were to compare perioperative characteristics of users vs. non-users of the SSC and to assess circumstances of the SSC application. A total of 213 of 234 (91 %) urological departments were users of the SSC, and 21 (9 %) were non-users. SSC users had more often a standard protocol, took less time and had fewer people involved for checking perioperative patient data compared to non-users. Financial budgeting for the SSC existed in 55 (24 %) departments and for patient safety in 73 (32 %) departments. The usage rate of the SSC in urological departments in Germany is high despite restricted financial budgeting. Users of the SSC profit by saving time and manpower for checking perioperative patient data.
- 10 November 2015
- Published by Springer Nature in Patient Safety in Surgery
- Vol. 9 (1) , 37
Open AccessUtilization of surgical safety checklists by urological surgeons in Germany: a nationwide prospective survey
We aimed to investigate the contemporary usage rate and habits of the WHO Surgical Safety Checklist (SSC) in German urological departments. We designed a 26-item questionnaire that was sent to all urological departments in Germany. The primary aim of this study was to evaluate the usage rate of the SSC. Secondary aims were to compare perioperative characteristics of users vs. non-users of the SSC and to assess circumstances of the SSC application. A total of 213 of 234 (91 %) urological departments were users of the SSC, and 21 (9 %) were non-users. SSC users had more often a standard protocol, took less time and had fewer people involved for checking perioperative patient data compared to non-users. Financial budgeting for the SSC existed in 55 (24 %) departments and for patient safety in 73 (32 %) departments. The usage rate of the SSC in urological departments in Germany is high despite restricted financial budgeting. Users of the SSC profit by saving time and manpower for checking perioperative patient data.
- Open Access
- 1 June 2015
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 41 (3) , 486-495
Feasibility, complications and oncologic results of a limited inguinal lymph node dissection in the management of penile cancer
Key words: Penile Neoplasms; Neoplasm Metastasis; Lymph Node Excision; Morbidity; Recurrence
- 1 June 2015
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 41 (3) , 486-495
Open AccessFeasibility, complications and oncologic results of a limited inguinal lymph node dissection in the management of penile cancer
Key words: Penile Neoplasms; Neoplasm Metastasis; Lymph Node Excision; Morbidity; Recurrence
- Open Access
- 14 May 2015
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 34 (1) , 1-8
sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
Measurement of prostate-specific antigen (PSA) advanced the diagnostic and prognostic potential for prostate cancer (PCa). However, due to PSA’s lack of specificity, novel biomarkers are needed to improve risk assessment and ensure optimal personalized therapy. A set of protein molecules as potential biomarkers was therefore evaluated in serum of PCa patients. Serum samples from patients undergoing radical prostatectomy (RPE) for biopsy-proven PCa without neoadjuvant treatment were compared to serum samples from healthy subjects. Preliminary screening of 119 proteins in 10 PCa patients and 10 controls was carried out by the Proteome Profiler Antibody Array. Those markers showing distinct differences between patients and controls were then further evaluated by ELISA in the serum of 165 PCa patients and 19 controls. Uni- and multivariate as well as correlation analysis were performed to test the capability of these molecules to detect disease and predict pathological outcome. Screening showed that soluble (s)E-cadherin, E-selectin, MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin warranted further evaluation. sE-Cadherin, TIMP1, Galectin and Clusterin were significantly over- and MMP9 under-expressed in PCa compared to controls. The concentration of sE-cadherin, MMP2 and Clusterin correlated negatively and that of MMP9 and TIMP1 positively with the Gleason Sum at prostatectomy. Only sE-cadherin significantly correlated with the highest Gleason pattern. Compared to serum PSA, sE-cadherin provided an independent and better matching predictive ability for discriminating PCas with an upgrade at RPE and aggressive tumors with a Gleason Sum ≥7. sE-cadherin performed most favorably from a large panel of serum proteins in terms of diagnostic and predictive potential in curatively treatable PCa. sE-cadherin merits further investigation as a biomarker for PCa.
- 14 May 2015
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 34 (1) , 1-8
Open AccesssE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
Measurement of prostate-specific antigen (PSA) advanced the diagnostic and prognostic potential for prostate cancer (PCa). However, due to PSA’s lack of specificity, novel biomarkers are needed to improve risk assessment and ensure optimal personalized therapy. A set of protein molecules as potential biomarkers was therefore evaluated in serum of PCa patients. Serum samples from patients undergoing radical prostatectomy (RPE) for biopsy-proven PCa without neoadjuvant treatment were compared to serum samples from healthy subjects. Preliminary screening of 119 proteins in 10 PCa patients and 10 controls was carried out by the Proteome Profiler Antibody Array. Those markers showing distinct differences between patients and controls were then further evaluated by ELISA in the serum of 165 PCa patients and 19 controls. Uni- and multivariate as well as correlation analysis were performed to test the capability of these molecules to detect disease and predict pathological outcome. Screening showed that soluble (s)E-cadherin, E-selectin, MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin warranted further evaluation. sE-Cadherin, TIMP1, Galectin and Clusterin were significantly over- and MMP9 under-expressed in PCa compared to controls. The concentration of sE-cadherin, MMP2 and Clusterin correlated negatively and that of MMP9 and TIMP1 positively with the Gleason Sum at prostatectomy. Only sE-cadherin significantly correlated with the highest Gleason pattern. Compared to serum PSA, sE-cadherin provided an independent and better matching predictive ability for discriminating PCas with an upgrade at RPE and aggressive tumors with a Gleason Sum ≥7. sE-cadherin performed most favorably from a large panel of serum proteins in terms of diagnostic and predictive potential in curatively treatable PCa. sE-cadherin merits further investigation as a biomarker for PCa.
- 1 April 2015
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 193 (4S)
MP8-11 QUALITY, ACCESSIBILITY AND READABILITY OF ONLINE HEALTH INFORMATION ON URINARY INCONTINENCE
- 1 April 2015
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 193 (4S)
MP8-11 QUALITY, ACCESSIBILITY AND READABILITY OF ONLINE HEALTH INFORMATION ON URINARY INCONTINENCE
- Open Access
- 26 March 2015
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 19 (8) , 1795-1804
Intensified antineoplastic effect by combining an HDAC‐inhibitor, an mTOR‐inhibitor and low dosed interferon alpha in prostate cancer cells
A significant proportion of men diagnosed with prostate cancer (PCa) eventually develop metastatic disease, which progresses to castration resistance, despite initial response to androgen deprivation. As anticancer therapy has become increasingly effective, acquired drug resistance has emerged, limiting efficacy. Combination treatment, utilizing different drug classes, exemplifies a possible strategy to foil resistance development. The effects of the triple application of the histone deacetylase (HDAC) inhibitor valproic acid (VPA), the mammalian target of rapamycin inhibitor everolimus and low dosed interferon alpha (IFNα) on PCa cell growth and dissemination capacity were investigated. For that purpose, the human PCa cell lines, PC‐3, DU‐145 and LNCaP were treated with the combined regimen or separate single agents. Cell growth was investigated by the MTT dye reduction assay. Flow cytometry served to analyse cell cycle progression. Adhesion to vascular endothelium or immobilized collagen, fibronectin and laminin was quantified. Migration and invasion characteristics were determined by the modified Boyden chamber assay. Integrin α and β subtypes were investigated by flow cytometry, western blotting and RT‐PCR. Integrin related signalling, Epidermal Growth Factor Receptor (EGFr), Akt, p70S6kinase and extracellular signal‐regulated kinases (ERK)1/2 activation were also assessed. The triple application of VPA, everolimus and low dosed IFNα blocked tumour cell growth and dissemination significantly better than any agent alone. Antitumour effects were associated with pronounced alteration in the cell cycle machinery, intracellular signalling and integrin expression profile. Combining VPA, everolimus and low dosed IFNα might be a promising option to counteract resistance development and improve outcome in PCa patients.
- 26 March 2015
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 19 (8) , 1795-1804
Open AccessIntensified antineoplastic effect by combining an HDAC‐inhibitor, an mTOR‐inhibitor and low dosed interferon alpha in prostate cancer cells
A significant proportion of men diagnosed with prostate cancer (PCa) eventually develop metastatic disease, which progresses to castration resistance, despite initial response to androgen deprivation. As anticancer therapy has become increasingly effective, acquired drug resistance has emerged, limiting efficacy. Combination treatment, utilizing different drug classes, exemplifies a possible strategy to foil resistance development. The effects of the triple application of the histone deacetylase (HDAC) inhibitor valproic acid (VPA), the mammalian target of rapamycin inhibitor everolimus and low dosed interferon alpha (IFNα) on PCa cell growth and dissemination capacity were investigated. For that purpose, the human PCa cell lines, PC‐3, DU‐145 and LNCaP were treated with the combined regimen or separate single agents. Cell growth was investigated by the MTT dye reduction assay. Flow cytometry served to analyse cell cycle progression. Adhesion to vascular endothelium or immobilized collagen, fibronectin and laminin was quantified. Migration and invasion characteristics were determined by the modified Boyden chamber assay. Integrin α and β subtypes were investigated by flow cytometry, western blotting and RT‐PCR. Integrin related signalling, Epidermal Growth Factor Receptor (EGFr), Akt, p70S6kinase and extracellular signal‐regulated kinases (ERK)1/2 activation were also assessed. The triple application of VPA, everolimus and low dosed IFNα blocked tumour cell growth and dissemination significantly better than any agent alone. Antitumour effects were associated with pronounced alteration in the cell cycle machinery, intracellular signalling and integrin expression profile. Combining VPA, everolimus and low dosed IFNα might be a promising option to counteract resistance development and improve outcome in PCa patients.
- Open Access
- 13 October 2014
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 47 (2) , 306-312
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa. Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested. The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading. Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.
- 13 October 2014
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 47 (2) , 306-312
Open AccessCCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa. Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested. The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading. Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.